Keeping you up to date on recent developments in orthopedics, including: HSS bone study sheds light on complications after spinal surgery; Simplify Medical reports first implant of its cervical artificial disc in the U.S. following FDA 1-Level approval; Scientists say xenon improves properties of maxillofacial and orthopedic implants.
Using in vivo imaging technology, investigators at the University of Utah and the University of Padua have identified a new signaling mechanism for glutamate that was linked to the onset of spreading depression or spreading depolarization, a neuronal activity pattern that plays a role in multiple neurological disease states.
Keeping you up to date on recent developments in oncology, including: Study clarifies distinct genomic features of early-onset appendiceal cancer; MET no better than EMT for cancer metastases; MRI may offer risk-stratification for glioblastoma; Study supports short telomeres as protective against cancer.
In terms of cellular diversity, it may not be the brain, but the kidney boasts more cell types than most other organs. Now, researchers have used single-cell RNA sequencing to identify further subtypes of cells in the kidney, and gain new insights into the molecular mechanisms of chronic kidney disease.
Keeping you up to date on recent developments in cardiology, including: Genes influencing CAD identified; Education reassures patients with noncardiac chest pain; Skin helps predict heart disease.
Keeping you up to date on recent developments in neurology, including: Genetic differences important in Alzheimer’s diagnosis; Stanford develops tool for studying neural activity; Gut microbiota plays a role in brain function, mood regulation.
LONDON – A study of genetic variants in patients with life-threatening COVID-19 has shed light on the mechanisms that underpin severe disease, uncovered new drug targets and pointed to approved drugs, including JAK inhibitors and phosphodiesterase type 4 inhibitors, as therapies that could aid recovery.
Keeping you up to date on recent developments in diagnostics, including: Predicting breast cancer recurrence, Comparing SARS-CoV-2 PCR tests, Paying attention to the little guy in proteomics, Increasing biomarker reproducibility
Data presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) – held, of course, in cyberspace and not San Antonio this year – added to the evidence that adding Verzenio (abemaciclib, Eli Lilly and Co.) to endocrine therapy for up to two years benefited women with high-risk, early stage hormone receptor-driven and HER2-negative breast cancer.
RSS
